These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

926 related items for PubMed ID: 17686163

  • 1. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A.
    Malar J; 2007 Aug 08; 6():107. PubMed ID: 17686163
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Cao Y, Hayashi CTH, Araujo MDS, Tripathi AK, Andrade AO, Medeiros JF, Vinetz J, Kumar N.
    Vaccine; 2024 Aug 30; 42(21):126140. PubMed ID: 39033079
    [Abstract] [Full Text] [Related]

  • 3. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T, Komesu A, Otsuki H, Sattabongkot J, Udomsangpetch R, Matsumoto Y, Tsuji N, Wu Y, Torii M, Tsuboi T.
    Infect Immun; 2005 Nov 30; 73(11):7375-80. PubMed ID: 16239536
    [Abstract] [Full Text] [Related]

  • 4. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
    Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP.
    PLoS One; 2008 Jul 09; 3(7):e2636. PubMed ID: 18612426
    [Abstract] [Full Text] [Related]

  • 5. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Blagborough AM, Yoshida S, Sattabongkot J, Tsuboi T, Sinden RE.
    Vaccine; 2010 Aug 23; 28(37):6014-20. PubMed ID: 20637303
    [Abstract] [Full Text] [Related]

  • 6. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
    Kongkasuriyachai D, Bartels-Andrews L, Stowers A, Collins WE, Sullivan J, Sattabongkot J, Torii M, Tsuboi T, Kumar N.
    Vaccine; 2004 Aug 13; 22(23-24):3205-13. PubMed ID: 15297075
    [Abstract] [Full Text] [Related]

  • 7. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.
    Coban C, Philipp MT, Purcell JE, Keister DB, Okulate M, Martin DS, Kumar N.
    Infect Immun; 2004 Jan 13; 72(1):253-9. PubMed ID: 14688103
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T, Harakuni T, Sugawa H, Sattabongkot J, Kato A, Tachibana M, Torii M, Tsuboi T, Arakawa T.
    Vaccine; 2011 Mar 24; 29(15):2720-6. PubMed ID: 21315699
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
    Mlambo G, Maciel J, Kumar N.
    Infect Immun; 2008 May 24; 76(5):2018-24. PubMed ID: 18316385
    [Abstract] [Full Text] [Related]

  • 15. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
    Miura K, Takashima E, Deng B, Tullo G, Diouf A, Moretz SE, Nikolaeva D, Diakite M, Fairhurst RM, Fay MP, Long CA, Tsuboi T.
    Infect Immun; 2013 Dec 24; 81(12):4377-82. PubMed ID: 24042109
    [Abstract] [Full Text] [Related]

  • 16. Transmission blocking malaria vaccines: Assays and candidates in clinical development.
    Sauerwein RW, Bousema T.
    Vaccine; 2015 Dec 22; 33(52):7476-82. PubMed ID: 26409813
    [Abstract] [Full Text] [Related]

  • 17. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
    Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N, Rungruang T, Cao YM, Stowers AW, Sirichaisinthop J, Coleman RE, Torii M.
    Am J Trop Med Hyg; 2003 Nov 22; 69(5):536-41. PubMed ID: 14695092
    [Abstract] [Full Text] [Related]

  • 18. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
    Jones RM, Chichester JA, Manceva S, Gibbs SK, Musiychuk K, Shamloul M, Norikane J, Streatfield SJ, van de Vegte-Bolmer M, Roeffen W, Sauerwein RW, Yusibov V.
    Hum Vaccin Immunother; 2015 Nov 22; 11(1):124-32. PubMed ID: 25483525
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.
    Arévalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincón A, Saul A, Mu J, Long C, Miller L, Herrera S.
    Am J Trop Med Hyg; 2005 Nov 22; 73(5 Suppl):32-7. PubMed ID: 16291764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.